$1.15
+0.07 (+6.48%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IMRN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 2 with posted results
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.NCT05933525results2026-06-12Protective Efficacy of a Single Daily Dose of Travelan Against Moderate-to-severe Diarrhea Following Challenge With Enterotoxigenic E. Coli (ETEC) Strain H10407.Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Biological: Travelan · Other: Placebo | Diarrhea, Travelers Diarrhea, Infectious Diarrhea | 63 | 2024-07-01actual | 2026-06-12 |
| Treatment for Clostridium-difficile Infection With IMM529NCT03065374Adverse events incidenceRandomized · Triple-masked · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was stopped due to slow recruitment. All subjects completed their participation including follow up period per protocol. No safety issues. | Biological: IMM-529 · Other: Placebo | Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence | 9 | 2019-11-07actual | 2019-12-26 |
| A Phase ll Study of IMM-124E for Patients With Non-alcoholic SteatohepatitisNCT02316717results2020-02-21Safety Outcome MeasureRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: IMM-124E · Other: Placebo | Non-alcoholic Steatohepatitis (NASH) | 133 | 2017-10-30actual | 2020-02-21 |
| Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic SteatohepatitisNCT01466894Safety outcomeRandomized · Triple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor administrative decision | Biological: IMM 124-E, Placebo | Nonalcoholic Steatohepatitis | 0 | Dec 2013 | 2012-12-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19